This Is MS Multiple Sclerosis Community: Knowledge & Support

Adeona Pharmaceuticals, Inc. announced that the Company's drug candidate, Trimesta™ (oral estriol), will be utilized in a new Phase II clinical trial to evaluate its potential therapeutic effect on cognitive dysfunction observed in female multiple sclerosis (MS) patients. The Skirball Foundation and Adeona have pledged to equally support this clinical trial led by Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, Department of Neurology. The study, which focuses on cognition loss in MS patients, also received contributions from numerous supporters, such as the Sherak Family Fund, the Gustafson Fund, and the Diamont family.

"At some point, 50-65 percent of MS patients will develop problems due to cognitive loss, yet there remains no treatment to target this profound disability. Unfortunately, loss of cognition affects a person's ability to work and is the major reason MS patients stop or decrease their level of work," said Dr. Voskuhl, Principal Investigator. "We are therefore thrilled to begin this novel clinical trial of Trimesta in which the primary endpoint is improvement in cognition and the ultimate goal is to address an unmet need for these patients."... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1878

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis

Haven't they got bored to death, yet, announcing rubbish? Should I be happy now? When is the "applause" light going to turn on?

Idiots...

_________________
Shortest joke: "We may not be able to cure MS but we can manage its symptoms."